Nucana presents data at the aacr 2023 annual meeting highlighting novel nuc-7738 mechanisms of action

Nuc-7738 reduces secreted forms of pd-l1 indicating potential synergy with checkpoint inhibitors nuc-7738 decreases glutaminase in vitro and in cancer tissue demonstrating potential for anti-cancer activity in highly metabolic tumors orlando, fla., april 14, 2023 (globe newswire) -- nucana plc (nasdaq: ncna) announced two posters to be presented at the american association of cancer research (aacr) annual meeting being held from april 14-19, 2023.
NCNA Ratings Summary
NCNA Quant Ranking